Global Hospital Acquired Infection Diagnostics Market Trends, Analysis, Growth, and Forecast: 2018 to 2027

MarketResearch.biz delivers in-depth insights on the global hospital acquired infection diagnostics market in its upcoming report titled, “Global Hospital Acquired Infection Diagnostics Market Trends, Applications, Analysis, Growth, and Forecast: 2018 to 2027”. The global hospital acquired infection diagnostics market is estimated to register a CAGR of X.X% in terms of value during forecast period 2018–2027. The report offers in-depth insights, revenue details, and other vital information regarding the target market, and the various trends, drivers, restraints, opportunities, and threats till 2027. The report offers insightful and detailed information regarding the various key players operating in the market, their financials, supply chain trends, technological innovations, key developments, apart from future strategies, acquisitions & mergers, and market footprint. The global hospital acquired infection diagnostics market report has been segmented on the basis of infection type, test type, and region.

Request Covid - 19 Impact

Hospital acquired infection are caught while patient is hospitalized. Hospital acquired infection are caused due to bacterial, viral, and fungal pathogens. Hospital acquired infection occurs up to 48 hours after hospital admission, or up to 3 days after discharge or up to 30 days after an operation. The most common types of hospital acquired infection are surgical site infection, gastroenteritis, urinary tract infection, and pneumonia. Hospital acquired infection can be instigated from another infected patient, outside environment or it can be originated from the patient's body, which become opportunistic after surgery or other procedure.

Increasing incidence of hospital acquired infection is expected to create demand for hospital acquired infection diagnostics products which in turn is expected to drive the global hospital acquired infection diagnostics market over the forecast period. In addition, geriatric population are more prone to hospital acquired infection and rapidly growing ageing population is expected to propel the market growth over the forecast period. Furthermore, technological advancements by manufactures for hospital acquired infection diagnostic products is other factor which in turn is expected to create demand for global hospital acquired infection diagnostics market.

However, decreasing prevalence of nosocomial infection in the developed countries owing to improved healthcare infrastructure is major factors expected to restrain the global hospital acquired infection diagnostics market growth over the forecast period.

North America market dominates the global hospital acquired infection diagnostics market in terms of revenue contribution as compared to that of markets in other regions. This is attributed to the wide availability diagnostics products for hospital acquired infection and favorable government funding in the region. Europe accounts for second-largest revenue share contribution to the global hospital acquired infection diagnostics market, followed by markets in the Asia Pacific, Latin America, and the Middle East & Africa respectively. The market in the Asia Pacific is projected to register comparatively faster growth in terms of revenue over the next 10 years. This is attributed owing to rapidly growing ageing population, high prevalence of nosocomial infection in the region.

Global hospital acquired infection diagnostics market segmentation, by infection type:

• Urinary Tract Infection (UTI)
• Blood Stream Infection (BSI)
• Surgical Site Infections (SSI)
• Hospital Acquired Pneumonia
• Others

 Global hospital acquired infection diagnostics market segmentation, by test type:

• Molecular Diagnostics
• Other in-vitro diagnostics tests

 Global hospital acquired infection diagnostics market segmentation, by region:

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

• Abbott Laboratories
• AdvanDx, Inc.
• Alere, Inc.
• Hoffmann-La Roche AG
• Becton, Dickinson and Company
• Cepheid Inc.
• Seegene, Inc.
• bioMérieux SA
• Merck & Company, Inc.
• Meridian Bioscience, Inc.